Autologous CAR T cell manufacturing using a semiautomatic, closed, modular workflow

Cell-based chimeric antigen receptor (CAR) T-cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and several US FDA-approved products already on the market.

In this application note, Thermo Fisher Scientific presents a digitally compatible, GMP-compliant, semiautomated manufacturing platform, which when used with Gibco™ CTS™ reagents, protocols and analytics, can result in consistent, efficacious CAR-T cell production.